85 related articles for article (PubMed ID: 16341049)
1. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism.
Mone AP; Cheney C; Banks AL; Tridandapani S; Mehter N; Guster S; Lin T; Eisenbeis CF; Young DC; Byrd JC
Leukemia; 2006 Feb; 20(2):272-9. PubMed ID: 16341049
[TBL] [Abstract][Full Text] [Related]
2. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab.
Zent CS; Secreto CR; LaPlant BR; Bone ND; Call TG; Shanafelt TD; Jelinek DF; Tschumper RC; Kay NE
Leuk Res; 2008 Dec; 32(12):1849-56. PubMed ID: 18584865
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia.
Cuesta-Mateos C; Loscertales J; Kreutzman A; Colom-Fernández B; Portero-Sáinz I; Pérez-Villar JJ; Terrón F; Muñoz-Calleja C
Cancer Immunol Immunother; 2015 Jun; 64(6):665-76. PubMed ID: 25724841
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.
Mamidi S; Höne S; Teufel C; Sellner L; Zenz T; Kirschfink M
Oncoimmunology; 2015 Mar; 4(3):e979688. PubMed ID: 25949896
[TBL] [Abstract][Full Text] [Related]
5. CLL patients: GIVe me three!
Kwok M; Stankovic T
Blood; 2023 Sep; 142(11):941-943. PubMed ID: 37707873
[No Abstract] [Full Text] [Related]
6. Cancer therapy with antibodies.
Paul S; Konig MF; Pardoll DM; Bettegowda C; Papadopoulos N; Wright KM; Gabelli SB; Ho M; van Elsas A; Zhou S
Nat Rev Cancer; 2024 Jun; 24(6):399-426. PubMed ID: 38740967
[TBL] [Abstract][Full Text] [Related]
7. Anti-NMDA and Anti-AMPA Receptor Antibodies in Central Disorders: Preclinical Approaches to Assess Their Pathological Role and Translatability to Clinic.
Olivero G; Roggeri A; Pittaluga A
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834353
[TBL] [Abstract][Full Text] [Related]
8. Advances in antibody-based therapy in oncology.
Zinn S; Vazquez-Lombardi R; Zimmermann C; Sapra P; Jermutus L; Christ D
Nat Cancer; 2023 Feb; 4(2):165-180. PubMed ID: 36806801
[TBL] [Abstract][Full Text] [Related]
9. Novel targeted therapies of T cell lymphomas.
Iżykowska K; Rassek K; Korsak D; Przybylski GK
J Hematol Oncol; 2020 Dec; 13(1):176. PubMed ID: 33384022
[TBL] [Abstract][Full Text] [Related]
10. Warm Autoimmune Hemolytic Anemia: Clinical Profile and Management.
Sudulagunta SR; Kumbhat M; Sodalagunta MB; Settikere Nataraju A; Bangalore Raja SK; Thejaswi KC; Deepak R; Mohammed AH; Sunny SP; Visweswar A; Suvarna M; Nanjappa R
J Hematol; 2017 Mar; 6(1):12-20. PubMed ID: 32300386
[TBL] [Abstract][Full Text] [Related]
11. Advances in targeted therapy for malignant lymphoma.
Wang L; Qin W; Huo YJ; Li X; Shi Q; Rasko JEJ; Janin A; Zhao WL
Signal Transduct Target Ther; 2020 Mar; 5(1):15. PubMed ID: 32296035
[TBL] [Abstract][Full Text] [Related]
12. Cancer Immunotherapies: Are They as Effective in the Elderly?
Poropatich K; Fontanarosa J; Samant S; Sosman JA; Zhang B
Drugs Aging; 2017 Aug; 34(8):567-581. PubMed ID: 28707274
[TBL] [Abstract][Full Text] [Related]
13. The immunological function of CD52 and its targeting in organ transplantation.
Zhao Y; Su H; Shen X; Du J; Zhang X; Zhao Y
Inflamm Res; 2017 Jul; 66(7):571-578. PubMed ID: 28283679
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.
Gross CC; Ahmetspahic D; Ruck T; Schulte-Mecklenbeck A; Schwarte K; Jörgens S; Scheu S; Windhagen S; Graefe B; Melzer N; Klotz L; Arolt V; Wiendl H; Meuth SG; Alferink J
Neurol Neuroimmunol Neuroinflamm; 2016 Dec; 3(6):e289. PubMed ID: 27766281
[TBL] [Abstract][Full Text] [Related]
15. Impact of Immune-Modulatory Drugs on Regulatory T Cell.
Furukawa A; Wisel SA; Tang Q
Transplantation; 2016 Nov; 100(11):2288-2300. PubMed ID: 27490409
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Chronic Lymphocytic Leukaemia (CLL).
Freeman CL; Gribben JG
Curr Hematol Malig Rep; 2016 Feb; 11(1):29-36. PubMed ID: 26857283
[TBL] [Abstract][Full Text] [Related]
17. Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab.
Dubey D; Cano CA; Stuve O
Neuropsychiatr Dis Treat; 2015; 11():2405-14. PubMed ID: 26425095
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of a Novel Anti-CD52 Antibody with Improved Efficacy and Reduced Immunogenicity.
Holgate RG; Weldon R; Jones TD; Baker MP
PLoS One; 2015; 10(9):e0138123. PubMed ID: 26372145
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
